Natera, Inc. (NTRA) Latest Company News

Nov 4, 2026, 12:00 UTC
Natera announced three peer-reviewed publications highlighting the clinical performance and actionability of its Signatera test in head and neck squamous cell carcinoma.
Source:
- businesswire.com
Oct 26, 2026, 11:00 UTC
Natera announced new data from 18 abstracts, including three oral presentations, on the value of its Renasight genetic test for chronic kidney disease at Natera, Inc..
Source:
- businesswire.com
Oct 18, 2026, 22:10 UTC
Natera announced that 20 abstracts featuring its technology will be presented at the 2026 ESMO Annual Congress in Madrid from October 23 to 26.
Source:
- businesswire.com
Oct 14, 2026, 12:00 UTC
Purespring Therapeutics announced that it will give two oral presentations at ASN Kidney Week 2026 in Denver from October 21 to 25, covering PS-003 preclinical data and a global Alport syndrome genetic study.
Source:
- finanznachrichten.de
Oct 13, 2026, 11:30 UTC
Natera, Inc. and Transcode Therapeutics, Inc. announced a collaboration to support enrollment in TransCode’s Phase 2a trial of TTX-MC138 in patients with colorectal cancer.
Source:
- businesswire.com
- zacks.com
Oct 9, 2026, 12:00 UTC
The U.S. Food and Drug Administration granted Breakthrough Device designation to Natera's multi-cancer early detection assay.
Source:
- businesswire.com
Oct 7, 2026, 12:00 UTC
Natera announced enrollment of the first patients in an NYU Langone Health-sponsored randomized trial using Signatera to guide treatment escalation for advanced or metastatic melanoma.
Source:
- businesswire.com
Oct 6, 2026, 12:00 UTC
Natera presented new data on its Signatera test at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting, marking its first participation at the conference.
Source:
- businesswire.com
Oct 5, 2026, 12:00 UTC
Alliance Foundation Trials and Natera announced the launch of AFT-70 NAVIGATE, a global randomized phase III trial evaluating an MRD-guided treatment strategy using Natera's Signatera test and Genentech's oral selective estrogen receptor degrader with CDK4/6 inhibitor therapy in ER-positive/HER2-negative early breast cancer.
Source:
- businesswire.com
Sep 18, 2026, 17:47 UTC
Natera CEO and President Steven Leonard Chapman sold 1,698 shares of common stock on Sept. 1, 2026, under a Rule 10b5-1 plan amended in March 2026, per an SEC Form 4 filing.
Source:
- nasdaq.com
- finance.yahoo.com
Aug 25, 2026, 09:29 UTC
Callan Family Office LLC acquired a new position in Natera, Inc. by purchasing 3,582 shares valued at approximately $972,000 during the second quarter, as disclosed in a recent SEC filing.
Source:
- defenseworld.net
Aug 25, 2026, 07:55 UTC
Brandywine Managers LLC acquired a new stake of 14,588 shares in Natera, Inc., valued at approximately $3,960,000, as disclosed in a Form 13F filing with the SEC.
Source:
- defenseworld.net
Aug 7, 2026, 21:10 UTC
Natera shares soared over 20% to an all-time high on August 7, 2026, boosting the co-founder's billionaire status.
Source:
- forbes.com
Aug 6, 2026, 20:05 UTC
Natera reported financial results for the second quarter ended June 30, 2026, with total revenues of $752.8 million, up 37.7% year over year, and a gross margin of 64.5%.
Source:
Jul 16, 2026, 22:35 UTC
MolDx finalized a local coverage determination (LCD) that expands coverage for Natera's Prospera portfolio in the surveillance setting for solid organ allograft rejection.
Source:
- businesswire.com
Jun 5, 2026, 00:00 UTC
Natera, Inc. appointed Thomas Lynch as a Class I Director and member of the Board, effective June 2, 2026.

NTRA

Natera announced three peer-reviewed publications highlighting the clinical performance and actionability of its Signatera test in head and neck squamous cell carcinoma.

Natera announced new data from 18 abstracts, including three oral presentations, on the value of its Renasight genetic test for chronic kidney disease at Natera, Inc..

Natera announced that 20 abstracts featuring its technology will be presented at the 2026 ESMO Annual Congress in Madrid from October 23 to 26.

Purespring Therapeutics announced that it will give two oral presentations at ASN Kidney Week 2026 in Denver from October 21 to 25, covering PS-003 preclinical data and a global Alport syndrome genetic study.

Natera, Inc. and Transcode Therapeutics, Inc. announced a collaboration to support enrollment in TransCode’s Phase 2a trial of TTX-MC138 in patients with colorectal cancer.

The U.S. Food and Drug Administration granted Breakthrough Device designation to Natera's multi-cancer early detection assay.

Natera announced enrollment of the first patients in an NYU Langone Health-sponsored randomized trial using Signatera to guide treatment escalation for advanced or metastatic melanoma.

Natera presented new data on its Signatera test at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting, marking its first participation at the conference.

Natera CEO and President Steven Leonard Chapman sold 1,698 shares of common stock on Sept. 1, 2026, under a Rule 10b5-1 plan amended in March 2026, per an SEC Form 4 filing.

Callan Family Office LLC acquired a new position in Natera, Inc. by purchasing 3,582 shares valued at approximately $972,000 during the second quarter, as disclosed in a recent SEC filing.

Brandywine Managers LLC acquired a new stake of 14,588 shares in Natera, Inc., valued at approximately $3,960,000, as disclosed in a Form 13F filing with the SEC.

Natera shares soared over 20% to an all-time high on August 7, 2026, boosting the co-founder's billionaire status.

Natera reported financial results for the second quarter ended June 30, 2026, with total revenues of $752.8 million, up 37.7% year over year, and a gross margin of 64.5%.

MolDx finalized a local coverage determination (LCD) that expands coverage for Natera's Prospera portfolio in the surveillance setting for solid organ allograft rejection.

Natera, Inc. appointed Thomas Lynch as a Class I Director and member of the Board, effective June 2, 2026.